Navigation Links
New 3-D test method for biomaterials 'flat out' faster
Date:4/29/2008

A novel, three-dimensional (3-D) screening method for analyzing interactions between cells and new biomaterials could cut initial search times by more than half, researchers from the National Institute of Standards and Technology (NIST) and Rutgers University report in the new issue of Advanced Materials.* The technique, an advance over flat, two-dimensional screening methods, enables rapid assessment of the biocompatibility and other properties of materials designed for repairingor even rebuildingdamaged tissues and organs.

In what may be a first, the team demonstrated how to screen cellmaterial interactions in a biologically representative, but systematically altered, 3-D environment. The pivotal step in the experiment was the collaborators success in making so-called libraries of miniature porous scaffolds that are bone-like in structure but vary incrementally in chemical composition. Knowing how changes in scaffold ingredients influence cell responses, researchers can devise strategies for developing biomaterials optimized for particular therapies and treatments.

Until now, attempts to accelerate screening of candidate biomaterials have used flat films and surfaces. (See, for example, Designer Gradients Speed Surface Science Experiments, Tech Beat June 8, 2006. http://www.nist.gov/public_affairs/techbeat/tb2006_0608.htm#designer ) Along with other shortcomings, these two-dimensional substrates are neither consistent with cells normal 3-D environment inside the body nor with the most common intended use of biomaterials: creating scaffolds to encourage the growth of cells into functional 3-D tissues and organs.

Cells are very sensitive to the texture, shapes, and other three-dimensional features of their local environment inside the body, explains NIST biomaterial scientist Carl Simon. The large difference in structure between 2-D films and 3-D scaffolds should be considered when screening new materials.

On a series of plates, each about the size of a dollar bill and arrayed with 96 scaffolds the size of pencil erasers, the researchers conducted the equivalent of 672 individual tests. In all, the tests yielded data for eight separate but related investigations, each one using libraries of 36 incrementally varying scaffolds and 12 controls. On each plate, tests were performed concurrently.

The six cell-culture investigations and two studies of scaffold structure were completed in six days, as compared with 24 days for the traditional method of preparing and testing each sample individually.

In the cell culture experiments, the team analyzed how variations in the chemical makeup of the tiny scaffolds affected the ability of bone-building cells called osteoblasts to multiply and to adhere to scaffolds. The scaffold libraries were made by blending varying proportions of two different compounds prepared at Rutgers based on the amino acid tyrosine, which is a component of proteins found in hair, skin, and other parts of the body.

The project yielded a unique data set, where two materials have been tested side by side in both 2-D and 3-D. In this case, results with 2-D films were predictive of the trends observed with 3-D scaffolds. Further work is required to determine if this will hold true for other cell-material systems.


'/>"/>

Contact: Mark Bello
mark.bello@nist.gov
301-975-3776
National Institute of Standards and Technology (NIST)
Source:Eurekalert  

Related biology news :

1. Research identifies first method for testing, assessing drug treatments for Chagas disease
2. Fox Chase researchers discover a method for clamping down on a cancer-promoting enzyme
3. Queens develops safe green decontamination method
4. Cold Spring Harbor Protocols features methods to screen genomes and analyze evolution
5. A new method to identify mutated genes in human diseases
6. New method to estimate sea ice thickness
7. Powerful yet reliable proteomics techniques are the focus of a new methods book
8. RNA-based methods for developmental studies are featured in Cold Spring Harbor Protocols
9. Stowers Proteomics Center devises method for assigning probabilities to human protein interactions
10. New method developed to identify genetic determinants of Alzheimers disease
11. Feinstein researchers develop new genetic method and identify novel genes for schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New 3-D test method for biomaterials 'flat out' faster
(Date:1/12/2017)...  Trovagene, Inc. (NASDAQ: TROV ), a ... that it has signed agreements with seven strategic partners ... Middle East for commercialization of the ... wave of international distribution agreements for Trovagene,s CLIA based ... The initial partners will introduce Trovagene,s liquid biopsy ...
(Date:1/11/2017)... -- Michael Johnson, co-founder of Visikol Inc. a company originally funded with ... to the elite "Forbes 30 Under 30" list in the Science ... 20 fields nationwide to be recognized as a leader in business ... ... a PhD candidate at Rutgers University. Visikol ...
(Date:1/4/2017)... thousands of attendees at this year,s International Consumer Electronics Show (CES), ... devices and services, will be featuring its new line of ULTRA CONNECT ... special CES Exhibit Suite , the new upper arm and wrist smart ... product platform.  Continue Reading ... ...
Breaking Biology News(10 mins):
(Date:1/11/2017)... ... January 11, 2017 , ... ... Research show early promise of the investigational anti-cancer agent tucatinib (formerly ONT-380) against ... previous treatment regimens. Twenty-seven percent of these heavily pretreated patients saw clinical benefit ...
(Date:1/11/2017)... , ... January 11, 2017 , ... ... year and costing healthcare systems more than $23.7 billion, healthcare systems are ... , Among the most common sepsis-causing pathogens are bacteria and the yeast ...
(Date:1/11/2017)... ... 11, 2017 , ... Symbios Technologies, Inc., a ... Science Foundation (NSF) has awarded Symbios a Small Business Innovation Research (SBIR) ... the Symbios Tubular Plasma Reactor™ (TPR™) by scaling the system for first customer ...
(Date:1/11/2017)... 11, 2017  GenVec, Inc. (NASDAQ: ... today that its chief scientific officer, Douglas ...  "AdenoVerse™ platform for translational development of innovative gene ... the upcoming Phacilitate Cell & Gene Therapy World ... Florida.  Dr. Brough,s presentation will highlight the utility ...
Breaking Biology Technology: